Influence of genetic co‐mutation on chemotherapeutic outcome in NPM1 ‐mutated and FLT3‐ITD wild‐type AML patients
Cancer Medicine · 2024-08 · 13 (15)
DOI: 10.1002/cam4.70102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 09.08.2024. Verfasst von Quan Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Nucleophosmin, Leukemia, Myeloid, Acute, Mutation, Nuclear Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Nucleophosmin 1 ( NPM1 ) gene‐mutated acute myeloid leukemia ( NPM1 mut AML) is classified as a subtype with a favorable prognosis. However, some patients fail to achieve a complete remission or relapse after intensified chemotherapy. Genetic abnormalities in concomitant mutations contribute to heterogeneous prognosis of NPM1 mut AML patients.
Methods
In this study, 91 NPM1 ‐mutated and FLT3‐ITD wild‐type ( NPM1 mut /FLT3‐ITD wt ) AML patients with intermediate‐risk karyotype were enrolled to analyze the impact of common genetic co‐mutations on chemotherapeutic outcome.
Results
Our data revealed that TET1/2 (52/91, 57.1%) was the most prevalent co‐mutation in NPM1 mut AML patients, followed by IDH1/2 (36/91, 39.6%), DNMT3A (35/91, 38.5%), myelodysplastic syndrome related genes (MDS‐related genes) ( ASXL1 , BCOR , EZH2 , RUNX1 , SF3B1 , SRSF2 , STAG2 , U2AF1 and ZRSR2 genes) (35/91, 38.5%), FLT3‐TKD (27/91, 29.7%) and GATA2 (13/91, 14.3%) mutations. Patients with TET1/2 mut exhibited significantly worse relapse‐free survival (RFS) (median, 28.7 vs. not reached (NR) months; p = 0.0382) compared to patients with TET1/2 wt , while no significant difference was observed in overall survival (OS) (median, NR vs. NR; p = 0.3035). GATA2 mut subtype was associated with inferior OS (median, 28 vs. NR months; p < 0.0010) and RFS (median, 24 vs. NR months; p = 0.0224) compared to GATA2 wt . By multivariate analysis, GATA2 mut and MDS‐related genes mut were independently associated with worse survival.
Conclusion
Mutations in TET1/2 , GATA2 and MDS‐related genes were found to significantly influence the chemotherapeutic outcome of patients with NPM1 mut AML. The findings of our study have significant clinical implications for identifying patients who have an adverse response to frontline chemotherapy and provide a novel reference for further prognostic stratification of NPM1 mut /FLT3‐ITD wt AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Xuejie Jiang
Förderung
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Wu, Q., Zhang, Y., Yuan, B., Huang, Y., Jiang, L., Liu, F., Yan, P., Cheng, J., Long, Z., & Jiang, X. (2024). Influence of genetic co‐mutation on chemotherapeutic outcome in NPM1 ‐mutated and FLT3‐ITD wild‐type AML patients. Cancer Medicine, 13(15). https://doi.org/10.1002/cam4.70102
Vancouver
Wu Q, Zhang Y, Yuan B, Huang Y, Jiang L, Liu F, et al. Influence of genetic co‐mutation on chemotherapeutic outcome in NPM1 ‐mutated and FLT3‐ITD wild‐type AML patients. Cancer Medicine. 2024;13(15). doi:10.1002/cam4.70102
BibTeX
@article{Wu2024,
author = {Wu, Quan and Zhang, Yujiao and Yuan, Baoyi and Huang, Yun and Jiang, Ling and Liu, Fang and Yan, Ping and Cheng, Jiaying and Long, Zhiquan and Jiang, Xuejie},
title = {Influence of genetic co‐mutation on chemotherapeutic outcome in NPM1 ‐mutated and FLT3‐ITD wild‐type AML patients},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {15},
doi = {10.1002/cam4.70102}
}
EUVIMED